1
|
Düzel E, Acosta-Cabronero J, Berron D, Biessels GJ, Björkman-Burtscher I, Bottlaender M, Bowtell R, Buchem MV, Cardenas-Blanco A, Boumezbeur F, Chan D, Clare S, Costagli M, de Rochefort L, Fillmer A, Gowland P, Hansson O, Hendrikse J, Kraff O, Ladd ME, Ronen I, Petersen E, Rowe JB, Siebner H, Stoecker T, Straub S, Tosetti M, Uludag K, Vignaud A, Zwanenburg J, Speck O. European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimers Dement (Amst) 2019; 11:538-549. [PMID: 31388558 PMCID: PMC6675944 DOI: 10.1016/j.dadm.2019.04.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Introduction The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists. Methods EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization. Results The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials. Discussion The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.
Collapse
Affiliation(s)
- Emrah Düzel
- Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany.,Institute of Cognitive Neuroscience, University College London, London, UK.,Center for Behavioral Brain Science, Magdeburg, Germany
| | - Julio Acosta-Cabronero
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany.,Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, University College London, London, UK
| | - David Berron
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany.,7Lund University BioImaging Center, Lund University, Lund, Sweden
| | - Geert Jan Biessels
- Department of Neurology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Isabella Björkman-Burtscher
- 7Lund University BioImaging Center, Lund University, Lund, Sweden.,Departement of Radiology, Sahlgrenska Akademy, University of Gothenburg, Gothenburg, Sweden
| | | | - Richard Bowtell
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Mark V Buchem
- Department of Radiology, University Medical Center Leiden, Leiden, The Netherlands
| | - Arturo Cardenas-Blanco
- Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.,German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany
| | - Fawzi Boumezbeur
- NeuroSpin, CEA & Université Paris-Saclay, Gif-Sur-Yvette, France
| | - Dennis Chan
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Stuart Clare
- Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK
| | - Mauro Costagli
- Imago 7 Research Foundation, Pisa, Italy.,Laboratory of Medical Physics and Magnetic Resonance, IRCCS Stella Maris, Pisa, Italy
| | - Ludovic de Rochefort
- Center for Magnetic Resonance in Biology and Medicine (UMR 7339), CRMBM, CNRS - Aix Marseille Université, Marseille, France
| | - Ariane Fillmer
- Physikalisch-Technische Bundesanstalt (PTB), Berlin, Germany
| | - Penny Gowland
- Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK
| | - Oskar Hansson
- 7Lund University BioImaging Center, Lund University, Lund, Sweden.,Memory Clinic, Skåne University Hospital, Malmö, Sweden
| | - Jeroen Hendrikse
- Department of Neurology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Oliver Kraff
- Erwin L. Hahn Institute for Magnetic Resonance Imaging, University of Duisburg-Essen, Essen, Germany
| | - Mark E Ladd
- Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.,Faculty of Physics and Astronomy and Faculty of Medicine, University of Heidelberg, Heidelberg, Germany
| | - Itamar Ronen
- Department of Radiology, University Medical Center Leiden, Leiden, The Netherlands
| | - Esben Petersen
- Danish Center for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
| | - James B Rowe
- Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - Hartwig Siebner
- Danish Center for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.,Department of Neurology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark
| | - Tony Stoecker
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Sina Straub
- Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Michela Tosetti
- Imago 7 Research Foundation, Pisa, Italy.,Laboratory of Medical Physics and Magnetic Resonance, IRCCS Stella Maris, Pisa, Italy
| | - Kamil Uludag
- Center for Neuroscience Imaging Research, Institute for Basic Science and Department of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.,Techna Institute & Koerner Scientist in MR Imaging, University Health Network, Toronto, Ontario, Canada
| | | | - Jaco Zwanenburg
- Department of Neurology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Oliver Speck
- German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Magdeburg, Germany.,Center for Behavioral Brain Science, Magdeburg, Germany.,Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany.,Leibniz-Institute for Neurobiology (LIN), Magdeburg, Germany
| |
Collapse
|
2
|
Barrett TF, Dyvorne HA, Padormo F, Pawha PS, Delman BN, Shrivastava RK, Balchandani P. First Application of 7-T Magnetic Resonance Imaging in Endoscopic Endonasal Surgery of Skull Base Tumors. World Neurosurg 2017; 103:600-610. [PMID: 28359922 DOI: 10.1016/j.wneu.2017.03.088] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 03/18/2017] [Accepted: 03/20/2017] [Indexed: 01/16/2023]
Abstract
BACKGROUND Successful endoscopic endonasal surgery for the resection of skull base tumors is reliant on preoperative imaging to delineate pathology from the surrounding anatomy. The increased signal-to-noise ratio afforded by 7-T MRI can be used to increase spatial and contrast resolution, which may lend itself to improved imaging of the skull base. In this study, we apply a 7-T imaging protocol to patients with skull base tumors and compare the images with clinical standard of care. METHODS Images were acquired at 7 T on 11 patients with skull base lesions. Two neuroradiologists evaluated clinical 1.5-, 3-, and 7-T scans for detection of intracavernous cranial nerves and internal carotid artery (ICA) branches. Detection rates were compared. Images were used for surgical planning and uploaded to a neuronavigation platform and used to guide surgery. RESULTS Image analysis yielded improved detection rates of cranial nerves and ICA branches at 7 T. The 7-T images were successfully incorporated into preoperative planning and intraoperative neuronavigation. CONCLUSIONS Our study represents the first application of 7-T MRI to the full neurosurgical workflow for endoscopic endonasal surgery. We detected higher rates of cranial nerves and ICA branches at 7-T MRI compared with 3- and 1.5-T MRI, and found that integration of 7 T into surgical planning and guidance was feasible. These results suggest a potential for 7-T MRI to reduce surgical complications. Future studies comparing standardized 7-, 3-, and 1.5-T MRI protocols in a larger number of patients are warranted to determine the relative benefit of 7-T MRI for endonasal endoscopic surgical efficacy.
Collapse
Affiliation(s)
- Thomas F Barrett
- Department of Neurosurgery, Mount Sinai Medical Center, New York, NY, USA.
| | - Hadrien A Dyvorne
- The Translational and Molecular Imaging Institute, Mount Sinai Medical Center, New York, NY, USA
| | - Francesco Padormo
- The Translational and Molecular Imaging Institute, Mount Sinai Medical Center, New York, NY, USA
| | - Puneet S Pawha
- Department of Radiology, Mount Sinai Medical Center, New York, NY, USA
| | - Bradley N Delman
- Department of Radiology, Mount Sinai Medical Center, New York, NY, USA
| | - Raj K Shrivastava
- Department of Neurosurgery, Mount Sinai Medical Center, New York, NY, USA
| | - Priti Balchandani
- The Translational and Molecular Imaging Institute, Mount Sinai Medical Center, New York, NY, USA
| |
Collapse
|
3
|
Schumacher S, Pache F, Bellmann-Strobl J, Behrens J, Dusek P, Harms L, Ruprecht K, Nytrova P, Chawla S, Niendorf T, Kister I, Paul F, Ge Y, Wuerfel J, Sinnecker T. Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study. MAGMA 2016; 29:535-41. [PMID: 27072685 DOI: 10.1007/s10334-016-0554-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 03/21/2016] [Accepted: 03/22/2016] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To quantify the periventricular venous density in neuromyelitis optica spectrum disease (NMOSD) in comparison to that in patients with multiple sclerosis (MS) and healthy control subjects. MATERIALS AND METHODS Sixteen patients with NMOSD, 16 patients with MS and 16 healthy control subjects underwent 7.0-Tesla (7T) MRI. The imaging protocol included T2*-weighted (T2*w) fast low angle-shot (FLASH) and fluid-attenuated inversion recovery (FLAIR) sequences. The periventricular venous area (PVA) was manually determined by a blinded investigator in order to estimate the periventricular venous density in a region of interest-based approach. RESULTS No significant differences in periventricular venous density indicated by PVA were detectable in NMOSD versus healthy controls (p = 0.226). In contrast, PVA was significantly reduced in MS patients compared to healthy controls (p = 0.013). CONCLUSION Unlike patients with MS, those suffering from NMOSD did not show reduced venous visibility. This finding may underscore primary and secondary pathophysiological differences between these two distinct diseases of the central nervous system.
Collapse
Affiliation(s)
- Sophie Schumacher
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Florence Pache
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic
| | - Judith Bellmann-Strobl
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Janina Behrens
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Petr Dusek
- Institute of Neuroradiology, Universitätsmedizin Göttingen, Göttingen, Germany.,Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic
| | - Lutz Harms
- Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Klemens Ruprecht
- Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Petra Nytrova
- Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine, General University Hospital in Prague, Charles University in Prague, Prague, Czech Republic
| | - Sanjeev Chawla
- Department of Radiology, NYU School of Medicine, New York, NY, USA
| | - Thoralf Niendorf
- Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany
| | - Ilya Kister
- Department of Neurology, Multiple Sclerosis Care Center, NYU School of Medicine, New York, NY, USA
| | - Friedemann Paul
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. .,Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. .,Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. .,Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
| | - Yulin Ge
- Department of Radiology, NYU School of Medicine, New York, NY, USA
| | - Jens Wuerfel
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Institute of Neuroradiology, Universitätsmedizin Göttingen, Göttingen, Germany.,Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.,Medical Image Analysis Center AG (MIAC), Basel, Switzerland
| | - Tim Sinnecker
- NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.,Medical Image Analysis Center AG (MIAC), Basel, Switzerland.,Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany.,Department of Neurology, Universitätsspital Basel, Basel, Switzerland
| |
Collapse
|
4
|
Wittenborn TR, Larsen EKU, Nielsen T, Rydtoft LM, Hansen L, Nygaard JV, Vorup-Jensen T, Kjems J, Horsman MR, Nielsen NC. Accumulation of nano-sized particles in a murine model of angiogenesis. Biochem Biophys Res Commun 2013; 443:470-6. [PMID: 24321551 DOI: 10.1016/j.bbrc.2013.11.127] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Accepted: 11/27/2013] [Indexed: 01/09/2023]
Abstract
PURPOSE To evaluate the ability of nm-scaled iron oxide particles conjugated with Azure A, a classic histological dye, to accumulate in areas of angiogenesis in a recently developed murine angiogenesis model. MATERIALS AND METHODS We characterised the Azure A particles with regard to their hydrodynamic size, zeta potential, and blood circulation half-life. The particles were then investigated by Magnetic Resonance Imaging (MRI) in a recently developed murine angiogenesis model along with reference particles (Ferumoxtran-10) and saline injections. RESULTS The Azure A particles had a mean hydrodynamic diameter of 51.8 ± 43.2 nm, a zeta potential of -17.2 ± 2.8 mV, and a blood circulation half-life of 127.8 ± 74.7 min. Comparison of MR images taken pre- and 24-h post-injection revealed a significant increase in R2(*) relaxation rates for both Azure A and Ferumoxtran-10 particles. No significant difference was found for the saline injections. The relative increase was calculated for the three groups, and showed a significant difference between the saline group and the Azure A group, and between the saline group and the Ferumoxtran-10 group. However, no significant difference was found between the two particle groups. CONCLUSION Ultrahigh-field MRI revealed localisation of both types of iron oxide particles to areas of neovasculature. However, the Azure A particles did not show any enhanced accumulation relative to Ferumoxtran-10, suggesting the accumulation in both cases to be passive.
Collapse
Affiliation(s)
- Thomas R Wittenborn
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark.
| | - Esben K U Larsen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark; Department of Molecular Biology and Genetics, Aarhus University, C.F. Moellers Allé 3, 8000 Aarhus C, Denmark; The Lundbeck Foundation Nanomedicine Center for Individualized Management of Tissue Damage and Regeneration (LUNA), Aarhus University, Aarhus, Denmark
| | - Thomas Nielsen
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark; Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark
| | - Louise M Rydtoft
- Center of Functionally Integrative Neuroscience (CFIN), Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark
| | - Line Hansen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark; Department of Molecular Biology and Genetics, Aarhus University, C.F. Moellers Allé 3, 8000 Aarhus C, Denmark; The Lundbeck Foundation Nanomedicine Center for Individualized Management of Tissue Damage and Regeneration (LUNA), Aarhus University, Aarhus, Denmark
| | - Jens V Nygaard
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark; Department of Engineering, Aarhus University, Finlandsgade 22, 8000 Aarhus, Denmark
| | - Thomas Vorup-Jensen
- The Lundbeck Foundation Nanomedicine Center for Individualized Management of Tissue Damage and Regeneration (LUNA), Aarhus University, Aarhus, Denmark; Department of Biomedicine, Aarhus University, Bartholins Allé 6, 8000 Aarhus, Denmark
| | - Jørgen Kjems
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark; Department of Molecular Biology and Genetics, Aarhus University, C.F. Moellers Allé 3, 8000 Aarhus C, Denmark; The Lundbeck Foundation Nanomedicine Center for Individualized Management of Tissue Damage and Regeneration (LUNA), Aarhus University, Aarhus, Denmark
| | - Michael R Horsman
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark
| | - Niels Chr Nielsen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark; The Lundbeck Foundation Nanomedicine Center for Individualized Management of Tissue Damage and Regeneration (LUNA), Aarhus University, Aarhus, Denmark; Center for Insoluble Protein Structures (inSPIN) and Department of Chemistry, Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark
| |
Collapse
|